Novartis-Sun settle for Gleevec generic entry in 2016
This article was originally published in Scrip
Executive Summary
Novartis has settled patent litigation concerning Gleevec (imatinib mesylate) with Sun Pharma, allowing the Indian firm to launch a generic version of the product in the US in February 2016.